SER Serina Therapeutics, Inc.

NYSE serinatherapeutics.com


$ 4.84 $ -0.01 (-0.21 %)    

Friday, 17-Oct-2025 14:54:12 EDT
QQQ $ 604.81 $ 7.25 (1.21 %)
DIA $ 462.54 $ 3.18 (0.69 %)
SPY $ 665.09 $ 5.62 (0.85 %)
TLT $ 91.16 $ -0.07 (-0.08 %)
GLD $ 387.99 $ -9.20 (-2.32 %)
$ 4.89
$ 4.85
$ 4.80 x 1,000
$ 4.89 x 28
$ 4.84 - $ 4.84
$ 3.81 - $ 8.05
19,609
na
48.92M
$ 0.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-24-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-22-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ ...

Core News & Articles

Item 1.01 Entry into a Material Definitive Agreement On September 9, 2025, Serina Therapeutics, Inc., a Delaware corporation (t...

Core News & Articles

Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkin...

Core News & Articles

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Serina Therapeutics (AMEX:SER) with a Buy and maintains $15 pr...

Core News & Articles

SATS: 92% | EchoStar To Sell 3.45 GHz And 600 MHz Spectrum Licenses To AT&T For $23B, Establishes Hybrid MNO Agreement With...

Core News & Articles

Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ ...

Core News & Articles

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Serina Therapeutics (AMEX:SER) with a Buy rating an...

Core News & Articles

Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION